Biomarker ID | 655 |
PMID | 21592298 |
Year | 2011 |
Biomarker | enhancer of zeste homologue 2 (EZH2) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Progression Vs No Progression |
Odds Ratio/Hazard Ratio/Relative Risk | Univariate: RR: 2.0, (95% CI: 1.2–3.3) |
Effect on Pathways | Pathways Include:- Cell differentiation pathway,MicroRNAs in muscle cell differentiation, PRC2 complex long-term gene silencing through modification of histone tails,Interleukin-2 signaling pathway |
Experiment | Progression Free Survival Vs No Progression Free Survival |
Type of Biomarker | Prognostic |
Cohort | 247 patients with prostate cancer were undertaken for the study. GS distribution was as follows: GS < 7, n = 60 (24.3%); GS = 7, n = 79 (32.0%); and GS > 7, n = 108 (43.7%). |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.004 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | Did not reach statistical significance in multivariate models |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | EZH2 |